Sidewinder secures $137M to advance ‘precision’ ADCs
Sidewinder Therapeutics has raised $137 million in a Series B financing round that will be used to advance newer types of antibody-drug conjugates, or ADCs,...
Get our latest downloads and information first.
Complete the form below to subscribe to our weekly newsletter.
